Literature DB >> 10703678

Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis.

Johannes M Roob1, Gholamali Khoschsorur2, Andreas Tiran3, Jörg H Horina1, Herwig Holzer1, Brigitte M Winklhofer-Roob4.   

Abstract

Intravenous iron application to anemic patients on hemodialysis leads to an "oversaturation" of transferrin. As a result, non-transferrin-bound, redox-active iron might induce lipid peroxidation. To test the hypothesis that vitamin E attenuates lipid peroxidation in patients receiving 100 mg of iron(III) hydroxide sucrose complex intravenously during a hemodialysis session, 22 patients were investigated in a randomized cross-over design, either with or without a single oral dose of 1200 IU of all-rac-alpha-tocopheryl acetate taken 6 h before the hemodialysis session. Blood was drawn before and 30, 60, 90, 135, and 180 min after the start of the iron infusion, and areas under the curve (AUC0-180 min) of ratios of plasma malondialdehyde (MDA) to cholesterol and plasma total peroxides to cholesterol (two markers of lipid peroxidation) were determined as the outcome variables. At baseline of the session without vitamin E supplementation, plasma alpha-tocopherol concentrations (27.6 +/- 1.8 micromol/L) and ratios of alpha-tocopherol to cholesterol (5.88 +/- 1.09 mmol/mol) were normal, plasma MDA concentrations were above normal (1.20 +/- 0.28 micromol/ L), and bleomycin-detectable iron (BDI), indicating the presence of redox-active iron, was not detectable. Upon iron infusion, BDI and MDA concentrations increased significantly (P < 0.001). BDI concentrations explained the increase over baseline in MDA concentrations (MDA = 1.29 +/- 0.075 x BDI). Vitamin E supplementation, leading to a 68% increase in plasma alpha-tocopherol concentrations, significantly reduced the AUC0-180 min of MDA to cholesterol (P = 0.004) and peroxides to cholesterol (P = 0.002). These data demonstrate that a single oral dose of vitamin E attenuates lipid peroxidation in patients on hemodialysis receiving intravenous iron. Given that intravenous iron is applied repeatedly to patients on hemodialysis, this therapeutic approach may protect against oxidative stress-related degenerative disease in the long term.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10703678     DOI: 10.1681/ASN.V113539

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  18 in total

1.  Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects.

Authors:  H Zheng; X Huang; Q Zhang; S D Katz
Journal:  Kidney Int       Date:  2006-02       Impact factor: 10.612

Review 2.  Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD.

Authors:  Peter Van Buren; Ruben L Velez; Nosratola D Vaziri; Xin J Zhou
Journal:  Int Urol Nephrol       Date:  2011-07-10       Impact factor: 2.370

Review 3.  Vitamin E in renal therapeutic regiments.

Authors:  Mohamed Alaa Thabet; James C M Chan
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

Review 4.  The potential adverse effects of haemolysis.

Authors:  Francesca Rapido
Journal:  Blood Transfus       Date:  2017-05       Impact factor: 3.443

5.  Iron, oxidative stress, and clinical outcomes.

Authors:  Rajiv Agarwal
Journal:  Pediatr Nephrol       Date:  2007-11-21       Impact factor: 3.714

6.  Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients.

Authors:  Ko-Lin Kuo; Szu-Chun Hung; Yau-Huei Wei; Der-Cherng Tarng
Journal:  J Am Soc Nephrol       Date:  2008-05-21       Impact factor: 10.121

Review 7.  Physiology and pathophysiology of iron in hemoglobin-associated diseases.

Authors:  Thomas D Coates
Journal:  Free Radic Biol Med       Date:  2014-04-12       Impact factor: 7.376

Review 8.  Iron therapy for renal anemia: how much needed, how much harmful?

Authors:  Walter H Hörl
Journal:  Pediatr Nephrol       Date:  2007-01-06       Impact factor: 3.714

9.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

10.  Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype.

Authors:  Zaher Armaly; Amir Abd El Qader; Adel Jabbour; Kamal Hassan; Rawi Ramadan; Abdalla Bowirrat; Bishara Bisharat
Journal:  BMC Nephrol       Date:  2015-08-13       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.